Skip to main content
Quest Diagnostics

X Chromosome Dosage Drives Statin-Induced Dysglycemia and Mitochondrial Dysfunction

X Chromosome Dosage Drives Statin-Induced Dysglycemia and Mitochondrial Dysfunction

Authors: Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, Ronquillo E, Scheker K, Muñoz A, Kuang YL, Theusch E, Lu M, Sanchez G, Oni-Orisan A, Iribarren C, McPhaul MJ, Nomura DK, Knowles JW, Krauss RM, Medina MW, Reue K

Citation: Nat Commun. 2024 Jul 2;15(1):5571. doi: 10.1038/s41467-024-49764-2.

Specialties: Cardiology, Endocrinology, Genetics

Related content

Conference Presentation
Evaluating the impact of mitochondrial testing and non-coding variants on diagnostic yield of a comprehensive panel in patients with monogenic diabetes
On-Demand Webinar
Fighting the Ladykiller and side effects with Cholesterol Lowering Therapy
On-Demand Webinar
Women and Heart Disease: Is There Really a Sex Difference?
On-Demand Webinar
The Evolving Role of Nonstatin Medication in the Management of Hypercholesterolemia
Conference Presentation
HDL Containing Specific Proteins Blunts the Association with Cholesterol Efflux Capacity: Observations from the Dallas Heart Study

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.